Navigation Links
Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip

SUNNYVALE, Calif., April 30 /PRNewswire-FirstCall/ -- Arrayit Corporation (OTC Bulletin Board: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced today that it is developing a microarray-based diagnostic test to detect the H1N1 swine flu virus.

The Arrayit test will allow researchers and clinicians to detect the presence of the virus in infected patients and livestock and to distinguish the threatening mutated strain from less harmful variants in humans and swine. Using its state-of-the-art manufacturing facility, Arrayit plans to begin mass production of its test kits over the next several weeks. The H1N1 test kits will be sent to the Centers for Disease Control (CDC) for validation, then sold for emergency use by licensed clinics, laboratories and other health care organizations worldwide.

The 2009 swine flu outbreak has raised concerns at the CDC and the World Health Organization (WHO). The CDC and WHO believe that the current outbreak poses a pandemic risk because the H1N1 flu virus contains genetic elements from both the swine and human influenza viruses, allowing direct human-to-human transmission without the need for agricultural contact. The dangerous 2009 strain has little immunity in the human population, resistance to several common anti-viral drugs, and has caused serious illness and death.

Department of Health and Human Services spokesperson said, "In the event of an emerging pandemic, the CDC-IRR (Influenza Reagent Resource) will serve as a source of reagents for qualified laboratories to provide additional support. During a pandemic, laboratories will play a critical role in detecting and confirming initial cases, characterizing viruses, monitoring the progression of the pandemic, and selecting vaccine strains. Scientists around the world are concerned that the influenza virus could one day mutate and acquire the properties needed to quickly spread between people, resulting in a pandemic."

Arrayit's unique microarray platform allows the design, manufacture and distribution of H1N1 chip technology quickly and inexpensively, owing to the Company's unique and patented contact printing technology, versatile system architecture, and broad customer base. "Our team is able to leverage the most sophisticated and accurate gene testing available on the market today to rapidly and affordably bring this H1N1 flu chip test to market," said Rene Schena, Chief Executive Officer of Arrayit Corporation.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal third quarter ended September 30, 2008.

    Arrayit Corporation
    Tel: 408-744-1331

SOURCE Arrayit Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
2. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
3. R-CALF United Stockgrowers of America: Fighting for the U.S. Cattle Producer
4. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
5. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
6. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
7. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
8. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
9. Senesco Chooses VGXI to Produce Factor 5A Plasmid
10. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
11. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed ... on behalf of a home health care worker who provided companionship services for the ... care workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced ... in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for ... years, Brillianteen has been a treasured tradition for numerous families in the Evanston ...
Breaking Medicine News(10 mins):